Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin

J Dermatol. 2023 Apr;50(4):e115-e116. doi: 10.1111/1346-8138.16646. Epub 2022 Nov 22.

Authors

Ken-Ichi Hasui¹, Yoshio Kawakami¹, Tomoko Miyake¹, Yoji Hirai¹, Hayato Nomura¹, Kohei Edamura², Motoo Araki², Shin Morizane¹

Affiliations

¹ Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
² Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

PMID: 36412280
DOI: 10.1111/1346-8138.16646

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Blister / chemically induced
Carcinoma, Transitional Cell*
Humans
Skin Abnormalities*
Skin Diseases*
Urinary Bladder Neoplasms*

Substances

enfortumab vedotin
Antibodies, Monoclonal